官方QQ
官方微信
手机版
您的位置:首页 >硕士生导师>临床中药方向>详细内容

临床中药方向

李芸霞

92b7f1f06b774fc8add9cbcdbc4a66fc.Jpeg

一、个人简介

李芸霞,中药学博士后,研究员,博士生导师。省部级优秀人才计划入选者、第八届全国高等中医药院校优秀青年、四川省中医药管理局学术和技术带头人、四川省学术和技术带头人后备人选;中华中医药学会中药基础理论分会副主任委员,四川省医学传播学会药学传承与发展专委会常务委员,世界中医药学会联合会道地药材多维评价专业委员会常务理事,四川省食品药品检验检测院国家药品监督管理局中成药质量评价重点实验室学术委员会委员,威尼斯官网杏林学者计划“讲席教授”,《泰国中医药》、《天然药物研究与开发》、《药学研究》编委,受邀主编Evidence-Based Complementary and Alternative Medicine特刊Traditional Medicine in Liver Disease and Inflammation,Frontier in Pharmacology,Journal of Ethnopharmacology,Photomedicine等多本SCI杂志审稿人。

主要进行基于临床的中药安全性、有效性评价研究,以及基于药效物质基础的创新中药研发工作。秉承“系统中药”多维评价的指导思想,以中药的临床安全有效为核心出发点,围绕中药的品种、品质、制药、药性、药效及应用等方面进行了大量的研究工作,积累了较丰富的经验和较突出的研究成果。承担国家自然科学基金等项目25项,主持国家自然科学基金3项,四川省青年科技创新研究等部省级以上课题11项,主研国家重点基础研究发展计划(973计划)等部省级以上课题10余项。主编《连翘的系统研究与利用》专著,参编《系统中药学》、《中华道地药材》等10余部专著;近年来在Advanced Healthcare Material、Pharmacological research、Wiley Interdisciplinary Reviews-RNA、Journal of Neuroinflammation等杂志上发表论文130余篇,其中SCI论文85篇(第一作者或通讯作者77篇,五分以上文章42篇),核心期刊论文40余篇,授权专利3项,获四川省科学技术进步奖三等奖1项。

2015年担任博士生导师,累计指导培养博士研究生13人、硕士研究生23人。6名研究生获国家奖学金、4名研究生获四川省优秀毕业研究生、1名研究生获威尼斯98488十佳研究生、4名研究生获威尼斯98488优秀研究生、2名研究生获泰合健康奖励基金以及华神科技奖励基金等荣誉,指导本科生获得全国大学生药苑论坛创新成果二等奖。

 

二、代表性成果

(1)代表性论著

1. Lihong Gong#, Honglin Zhou#, Shenglin Zhang, Cheng Wang, Ke Fu, Cheng Ma, Yafang Zhang, Cheng Peng*, Yunxia Li*. CD44-targeting Drug Delivery System of Exosomes Loading Forsythiaside A Combats Liver Fibrosis via Regulating NLRP3-mediated Pyroptosis. Advanced healthcare materials, 2023: e2202228.(IF=11.092)(期刊论文)

2. Shu Dai#, Cheng Wang#, XingTao Zhao, Cheng Ma, Ke Fu, Yanfang Liu, Cheng Peng*, Yunxia Li*. Cucurbitacin B: a review of its pharmacology, toxicity, and pharmacokinetics. Pharmacological research, 2022, 187:106587.(IF=10.334)(期刊论文)

3. Xingtao Zhao, Xinyan Xue, Zhifu Cui, Felix Kwame Amevor, Yan Wan, Ke Fu, Cheng Wang, Cheng Peng*, Yunxia Li*. microRNAs-based diagnostic and therapeutic applications in Liver Fibrosis. Wiley Interdiscip Rev RNA, 2022, e1773.(IF=9.349)(期刊论文)

4. Lihong Gong, Cheng Wang, Honglin Zhou, Cheng Ma, Yafang Zhang, Cheng Peng*, Yunxia Li*. A review of pharmacological and pharmacokinetic properties of Forsythiaside A. Pharmacological research, 2021, 21:105690.(IF=10.334)(期刊论文)

5. Lihong Gong, Linyuan Yu, Xiaohong Gong, Cheng Wang, Naihua Hu, Xuyang Dai, Cheng Peng*, Yunxia Li*. Exploration of anti-inflammatory mechanism of forsythiaside A and forsythiaside B in CuSO4-induced inflammation in zebrafish by metabolomic and proteomic analyses. Journal of Neuroinflammation, 2020, 17(1): 173.(IF=9.587)(期刊论文)

6. Cheng Wang#, Cheng Ma#, Lihong Gong, Yuqin Guo, Ke Fu, Yafang Zhang, Honglin Zhou, Yunxia Li*. Macrophage polarization and its role in liver disease. Frontiers in Immunology, 2021, 12:803037.(IF=8.786)(期刊论文)

7. Cheng Ma#, Cheng Wang#, Yafang Zhang, Yanzhi Li, Ke Fu, Lihong Gong, Honglin Zhou, Yunxia Li*. Phillygenin inhibited M1 macrophage polarization and reduced hepatic stellate cell activation by inhibiting macrophage exosomal miR-125b-5p. Biomedicine & Pharmacotherapy, 2023, 159:114264.(IF=7.419)(期刊论文)

8. Xingtao Zhao, Cheng Wang, Shu Dai, Yanfang Liu, Fang Zhang, Cheng Peng*, Yunxia Li*. Quercetin protects ethanol-induced hepatocyte pyroptosis via scavenging mitochondrial ROS and promoting PGC-1α-regulated mitochondrial homeostasis in L02 cells, Oxidative Medicine and Cellular Longevity, 2022, 2022:4591134.(IF=7.310)(期刊论文)

9. Xingtao Zhao, Felix Kwame Amevor, Zhifu Cui, Yan Wan, Xinyan Xue, Cheng Peng*, Yunxia Li*. Steatosis in metabolic diseases: A focus on lipolysis and lipophagy. Biomedicine & Pharmacotherapy, 2023, 160:114311.(IF=7.419)(期刊论文)

10. Cheng Wang#, Honglin Zhou#, Rui Wu, Yuqin Guo, Lihong Gong, Ke Fu, Cheng Ma, Cheng Peng*, Yunxia Li*. Mesenchymal stem cell-derived exosomes and non-coding RNAs: Regulatory and therapeutic role in liver diseases. Biomedicine & pharmacotherapy, 2022, 157:114040.(IF=7.419)(期刊论文)

11. Xinyan Xue, Xingtao Zhao, Jing Wang, Cheng Wang, Cheng Ma, Yafang Zhang, Yunxia Li*, Cheng Peng*. Carthami flos extract against carbon tetrachloride-induced liver fibrosis via alleviating angiogenesis in mice. Phytomedicine, 2022, 108:154517.(IF=6.656)(期刊论文)

12. Yafang Zhang, Cheng Ma, Linfeng He, Li Liao, Chaocheng Guo, Cheng Wang, Lihong Gong, Honglin Zhou, Ke Fu, Cheng Peng*, Yunxia Li*. Tetramethylpyrazine protects endothelial injury and antithrombosis via antioxidant and anti-apoptosis in HUVECs and zebrafish. Oxidative Medicine and Cellular Longevity, 2022, 2022:2232365.(IF=7.310)(期刊论文)

13. Ke Fu#, Cheng Ma#, Cheng Wang, Honglin Zhou, Lihong Gong, Yafang Zhang, Yunxia Li*. Forsythiaside A alleviated carbon tetrachloride-induced liver fibrosis by modulating gut microbiota composition to increase short-chain fatty acids and restoring bile acids metabolism disorder. Biomedicine & Pharmacotherapy, 2022, 151:113185.(IF=7.419)(期刊论文)

14. Xingtao Zhao, Xinyan Xue, Jing Wang, Shu Dai, Cheng Peng*, Yunxia Li*. Quercetin alleviates ethanol-induced hepatic steatosis in L02 cells by activating TFEB translocation to compensate for inadequate autophagy. Phytotherapy Research, 2022:1-15.(IF=6.388)(期刊论文)

15. Mengting Zhou, Xingtao Zhao, Li Liao, Ying Deng, Meichen Liu, Jing Wang, Xinyan Xue, Yunxia Li*. Forsythiaside A regulates activation of hepatic stellate cells by inhibiting NOX4-dependent ROS. Oxidative Medicine and Cellular Longevity, 2022, 2022:9938392.(IF=7.310)(期刊论文)

16. Xuyang Dai, Linfeng He, Naihua Hu, Chaocheng Guo, Mengting Zhou, Xingtao Zhao, Cheng Wang, Lihong Gong, Cheng Ma, Xinyan Xue, Yunxia Li*. Polygoni Multiflori Radix Praeparata Ethanol Extract Exerts a Protective Effect Against High-Fat Diet Induced Non-Alcoholic Fatty Liver Disease in Mice by Remodeling Intestinal Microbial Structure and Maintaining Metabolic Homeostasis of Bile Acids. Frontiers in Pharmacology, 2021, 12:734670.(IF=5.988)(期刊论文)

17. Cheng Wang#, Cheng Ma#, Ke Fu, Lihong Gong, Yafang Zhang, Honglin Zhou, Yunxia Li*. Phillygenin attenuates carbon tetrachloride-induced liver fibrosis via modulating inflammation and gut microbiota. Frontiers in Pharmacology, 2021, 12:756924.(IF=5.988)(期刊论文)

18. Xinyan Xue, Ying Deng, Jing Wang, Mengting Zhou, Li Liao, Cheng Wang, Cheng Peng*, Yunxia Li*. Hydroxysafflor yellow A, a natural compound from Carthamus tinctorius L with good effect of alleviating atherosclerosis. Phytomedicine, 2021, 91:153694.(IF=6.656)(期刊论文)

19. Li Liao, Lihong Gong, Mengting Zhou, Xinyan Xue, Yunxia Li*, Cheng Peng. Leonurine ameliorates oxidative stress and insufficient angiogenesis by regulating the PI3K/Akt-eNOS signaling pathway in H2O2-induced HUVECs. Oxidative Medicine and Cellular Longevity, 2021, 2021:9919466.(IF=7.310)(期刊论文)

20. Ke Fu#, Honglin Zhou#, Cheng Wang, Lihong Gong, Cheng Ma, Yafang Zhang, Yunxia Li*. A review: pharmacology and pharmacokinetics of Schisandrin A. Phytotherapy Research, 2022, 36(6):2375-2393.(IF=6.388)((期刊论文)

 

(2)主要承担科研项目

1. 国家自然科学基金面上项目“司外揣内”活性成分谱桥接生物体代谢响应网络探究附子治疗心阳虚型慢性心衰的药效物质基础及作用机理, 64.8万元, 主持。

2. 国家自然科学基金面上项目, 多组分多靶点动态网络调控驱动效应模型研究连翘“清热解毒”的药效物质基础和协同作用机理70万元, 主持。

3. 国家自然科学基金青年项目, 连翘清热解毒药效物质基础的“谱证动力学”研究14万元,主持。

4. 国家自然科学基金地区联合基金项目, 川产道地药材的道地性研究247万元, 主研。

5. 国家自然科学基金重点项目, 附子“毒与效”的多维评价与整合分析研究275万元, 主研。

6. 国家重点基础研究计划(973计划), 基于西部道地药材的创新药物研究235万元, 主研。

7. 四川省科学技术厅基金, 外泌体介导的连翘“既病防变”多点协同抗肝纤维化的药效物质基础及作用机制研究, 40万元, 主持。

8. 四川省科学技术厅基金, 中医药理论指导下的中药安全性、有效性科学内涵研究四川省青年科技创新研究团队100万元, 主持。

9. 四川省科学技术厅基金, 连翘通过调节肠道菌群干预“肠-肝轴”TLR4/MyD88/NF-κB信号通路抗肝纤维化作用机制研究, 20万元, 主持。

 

(3)其他代表性研究成果和学术奖励

1. 李芸霞, 李燕, 刘美辰, 王斌, 张若琪, 谢晓芳, 龚小红, 龚莉虹, 周梦婷. 基于清热解毒功效的连翘防治肝纤维化关键技术建立及应用示范. 四川省科学技术进步奖三等奖, 2022年.(科研奖励)

2. Yunxia Li. Mutidemensional evaluation of Fosythiaside Fructus-under the guidance of systematic Traditional Chinese medicine, 1st New Zealand-China Non Communicable Disease Research Cooperation Forum, Dunedin and Queenstown, 2019年8月.(会议报告)

3. 李芸霞, 曹小玉, 彭成, 郑立, 汤韵秋, 余琳媛, 周忆梦, 全云云, 刘美辰. 一种连翘挥发油自微乳及其制备方法. 中国, ZL 201811279086.0(专利)

4. 李芸霞, 龚小红, 彭成, 党珏, 赵梦杰, 赵梦君, 罗林, 袁岸, 李燕. 生何首乌的HPLC指纹图谱检测方法. 中国, ZL 201610490084.0(专利)

5. 李芸霞, 罗林, 彭成, 党珏, 全云云, 袁岸, 龚莉虹, 胡乃华, 赵兴桃. 一种具有清热解毒作用的药物组合物及其制备方法. 中国, CN 201810134659.4(专利) 

终审:药学院管理员